middle.news
Paradigm Reaches Halfway Mark in Phase 3 Osteoarthritis Trial Ahead of August Readout
8:34am on Tuesday 31st of March, 2026 AEDT
•
Healthcare
Read Story
Paradigm Reaches Halfway Mark in Phase 3 Osteoarthritis Trial Ahead of August Readout
8:34am on Tuesday 31st of March, 2026 AEDT
Key Points
50% enrolment milestone reached in global PARA_OA_012 Phase 3 trial
Interim analysis scheduled for August 2026 to assess efficacy and safety
Trial design mirrors successful PARA_OA_008 study with key refinements
Use of weekly average daily pain recordings to reduce placebo bias
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PARADIGM BIOPHARMACEUTICALS LIMITED.. (ASX:PAR)
OPEN ARTICLE